Lisata Therapeutics, Inc. Sustainability Profile
Lisata Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for serious diseases. Founded in 2020, Lisata focuses on advancing its proprietary platform to create targeted treatments that address unmet medical needs, particularly in oncology and autoimmune disorders. With a commitment to scientific excellence, Lisata Therapeutics has achieved significant milestones, including the progression of its lead product candidates through various stages of clinical development. The company’s unique approach combines cutting-edge technology with a deep understanding of disease mechanisms, setting it apart in the competitive biopharmaceutical landscape. As it continues to expand its operational reach, Lisata is poised to make a substantial impact on patient care and therapeutic options in the industry.
DitchCarbon Score
How does Lisata Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lisata Therapeutics, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lisata Therapeutics, Inc.'s reported carbon emissions
In 2022, Lisata Therapeutics, Inc. reported total carbon emissions of approximately 686,600 kg CO2e. This figure comprises 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Comparatively, in 2021, the company’s emissions were significantly higher, with a total of approximately 533 million kg CO2e, all attributed to Scope 1 emissions. This indicates a substantial reduction in emissions from 2021 to 2022. Despite these reductions, Lisata Therapeutics has not established any specific reduction targets or climate pledges, nor do they have any commitments cascaded from a parent organisation. The absence of Scope 3 emissions data suggests a potential area for future reporting and improvement. Overall, while Lisata Therapeutics has made progress in reducing its carbon footprint, further commitments and transparency regarding its climate strategy could enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Lisata Therapeutics, Inc.'s Industry?
How Carbon Intensive is Lisata Therapeutics, Inc.'s Location?
Lisata Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lisata Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.